keyword
MENU ▼
Read by QxMD icon Read
search

Dmard therapy

keyword
https://www.readbyqxmd.com/read/28526972/patient-experiences-attitudes-and-expectations-towards-receiving-information-about-anti-tnf-medication-a-quantitative-study
#1
Jon Packham, Paul Arkell, Tom Sheeran, Ann Brownfield, Anthony Cadwgan, Sarah Ryan
The objective of the study was to measure patient attitudes and experience of information received during drug counselling for rheumatoid arthritis (RA) medications. This is a cross-sectional UK postal questionnaire study. Three RA patient groups-disease-modifying antirheumatic drugs (DMARDs) only, first anti-tumour necrosis factor (anti-TNF) and failed anti-TNF-were sent postal questionnaires. Data on patient history/demographics, drug counselling experience, knowledge of drug side effects, attitudes to vaccinations, cancer screening and blood borne virus testing was collected; 264/679 (39%) patients responded (median age 65 years, 66% female, median disease duration 15 years)...
May 19, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28524619/use-of-complementary-and-alternative-medicines-is-associated-with-delay-to-initiation-of-disease-modifying-anti-rheumatic-drug-therapy-in-early-inflammatory-arthritis
#2
Manjari Lahiri, Amelia Santosa, Lay Kheng Teoh, Jane A Clayton, Sheen Yee Lim, Gim Gee Teng, Peter P M Cheung
OBJECTIVES: To study the predictors of complementary and alternative medicine (CAM) use in patients with early inflammatory arthritis (EIA), and its impact on delay to initiation of disease-modifying anti-rheumatic drugs (DMARD). METHODS: Data were collected prospectively from EIA patients aged ≥ 21 years. Current or prior CAM use was ascertained by face-to-face interview. Predictors of CAM use and its effect on time to DMARD initiation were determined by multivariate logistic regression and Cox proportional hazards, respectively...
May 19, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28521841/tnf-inhibitors-appear-to-inhibit-disease-progression-and-improve-outcome-in-takayasu-arteritis-an-observational-population-based-time-trend-study
#3
Birgir Gudbrandsson, Øyvind Molberg, Øyvind Palm
BACKGROUND: Magnetic resonance imaging (MRI) and computed tomography (CT) angiography have now largely replaced interventional angiography in the diagnoses and follow up of Takayasu arteritis (TAK) but data on the effects of this change of imaging method on diagnostic delay and vascular damage, and detailed data on the effect of different treatment regimens on the accumulation of vascular damage are missing. The aim of this study was to assess time trends in diagnostic delay, therapeutic approaches, arterial lesion accrual, persistent disease activity and remission rates in TAK...
May 18, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28516872/glucocorticoid-sparing-effect-of-first-year-anti-tnf%C3%AE-treatment-in-rheumatoid-arthritis-corpus-cohort
#4
Carole Duquenne, Daniel Wendling, Jean Sibilia, Chantal Job-Deslandre, Loic Guillevin, Jacques Benichou, René Marc Flipo, Francis Guillemin, Alain Saraux
OBJECTIVES: Anti-TNFα agents are indicated in selected patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate and particularly when glucocorticoids are mandatory. We evaluated whether a glucocorticoid-sparing effect occurred during the first year of anti-TNF-α therapy. METHODS: Between 2007 and 2009, the French multicentre, longitudinal, prospective, observational, population-based CORPUS cohort included biologic-naive patients with inflammatory joint disease...
May 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28502927/mizoribine-synchronized-methotrexate-therapy-should-be-considered-when-treating-rheumatoid-arthritis-patients-with-an-inadequate-response-to-various-combination-therapies
#5
Keigo Ikeda, Kozo Watanabe, Takuya Hirai, Kana Tanji, Tomoko Miyashita, Shihoko Nakajima, Kaori Uomori, Shinji Morimoto, Kenji Takamori, Hideoki Ogawa, Yoshinari Takasaki, Iwao Sekigawa
Objective The objective of this study was to confirm the efficacy of low-dose mizoribine (MZR), an inhibitor of inosine monophosphate dehydrogenase, as part of synchronized methotrexate (MTX) therapy for rheumatoid arthritis (RA) patients with an inadequate response to various combination therapies of MTX, other synthetic disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. Methods Low-dose MZR was administered to 56 uncontrolled RA patients being treated with MTX and various biological DMARDs...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28496328/association-between-use-of-disease-modifying-antirheumatic-drugs-and-diabetes-in-patients-with-ankylosing-spondylitis-rheumatoid-arthritis-or-psoriasis-psoriatic-arthritis-a-nationwide-population-based-cohort-study-of-84-989-patients
#6
Hsin-Hua Chen, Der-Yuan Chen, Chi-Chen Lin, Yi-Ming Chen, Kuo-Lung Lai, Ching-Heng Lin
PURPOSE: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA). PATIENTS AND METHODS: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28487504/obinutuzumab-is-effective-in-chronic-lymphocytic-leukemia-and-rheumatoid-arthritis-after-rituximab-failure-a-case-report
#7
Curtis Lachowiez, Atul Deodhar, Eliana Kozin, Stephen Spurgeon
BACKGROUND Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting older adults. As such, many of these patients suffer from co-existing disease states, and the provider must take these comorbidities into account when determining a treatment regimen. The widespread use of monoclonal antibodies (mAbs) has drastically changed the treatment landscape of multiple diseases, ranging from leukemia to autoimmune conditions such as rheumatoid arthritis. CASE REPORT We present the case of a patient who had progression of his CLL and rheumatoid symptoms on rituximab therapy, and was subsequently treated with the second-generation anti-CD20 antibody obinutuzumab...
May 10, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28481462/biologics-or-tofacitinib-for-people-with-rheumatoid-arthritis-naive-to-methotrexate-a-systematic-review-and-network-meta-analysis
#8
REVIEW
Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell, George A Wells
BACKGROUND: Biologic disease-modifying anti-rheumatic drugs (biologics) are highly effective in treating rheumatoid arthritis (RA), however there are few head-to-head biologic comparison studies. We performed a systematic review, a standard meta-analysis and a network meta-analysis (NMA) to update the 2009 Cochrane Overview. This review is focused on the adults with RA who are naive to methotrexate (MTX) that is, receiving their first disease-modifying agent. OBJECTIVES: To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (methotrexate (MTX)/other DMARDs) in people with RA who are naive to methotrexate...
May 8, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28465764/sociodemographic-determinants-of-out-of-pocket-expenditures-for-patients-using-prescription-drugs-for-rheumatoid-arthritis
#9
Kumar Mukherjee, Khalid M Kamal
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease that has a substantial economic impact on patients. Patients with RA are at an increased risk for disability and for loss of income. The inclusion of biologic drugs in RA therapy has increased the cost of treatment. Little is known about the relationship between sociodemographic characteristics and the out-of-pocket (OOP) expenditures for prescription drugs for patients with RA, including biologics, disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics...
February 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28461647/utility-of-power-doppler-ultrasound-detected-synovitis-for-the-prediction-of-short-term-flare-in-psoriatic-patients-with-arthritis-in-clinical-remission
#10
Santiago Ruta, Josefina Marin, Maria Laura Acosta Felquer, Leandro Ferreyra-Garrot, Javier Rosa, Ricardo García-Monaco, Enrique R Soriano
OBJECTIVE: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA), but its value is not yet fully understood. The aim of this study was to evaluate PDUS features at joint level in patients with PsA in clinical remission and to investigate its value for predicting short-term flares. METHODS: Consecutive patients with PsA in clinical remission according to the attending rheumatologist and who fulfill minimal disease activity criteria and/or 28-joint Disease Activity Score in remission criteria underwent PDUS examination of 18 joints...
May 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28448195/design-characteristics-of-the-corrona-japan-rheumatoid-arthritis-registry
#11
Hisashi Yamanaka, Mitsumasa Kishimoto, Dimitrios A Pappas, Jeffrey D Greenberg, Joel M Kremer, Yoshiya Tanaka
OBJECTIVES: The primary objective is to prospectively study the comparative safety and effectiveness of older and newer classes of nonbiologic DMARDs (Disease-modifying antirheumatic drugs), biologic DMARDs and targeted synthetic therapies approved for rheumatoid arthritis (RA) in a real-world patient population in Japan. METHODS: Prospective, multicenter, noninterventional, observational study across geographic distribution of both private and public institutions for patients with RA who are newly prescribed one of the following medications: (1) methotrexate; (2) anti-TNF biologic DMARDs; (3) non-TNF biologic DMARDs; and (4) approved JAK inhibitors at the time of enrollment into the registry...
April 27, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28445107/hypodermal-adipose-tissue-sonoelastography-for-monitoring-treatment-response-in-patients-with-plaque-psoriasis
#12
Annunziata Dattola, Simone Altobelli, Salvatore Marsico, Domenico Plastina, Steven P Nistico, Armando Cavallo, Roberto Floris, Luca Bianchi, Manlio Guazzaroni
BACKGROUND: Psoriasis (PsO) is a multifactorial chronic and relapsing skin disease that affects about 125 million people in the world. Several studies have demonstrated the link between adipose tissue, inflammation, and PsO. The purpose of our study is to evaluate hypodermal adipose tissue inflammation underneath PsO plaques quantifying tissue elasticity with sonoelastography before and after treatment. The study was conducted at the Department of Dermatology of the University of "Rome Tor Vergata" and Department of Radiology of the University of "Rome Tor Vergata...
April 24, 2017: Photomedicine and Laser Surgery
https://www.readbyqxmd.com/read/28429118/-how-frequent-are-poor-prognostic-markers-in-rheumatoid-arthritis-an-estimate-based-on-three-epidemiologic-cohorts
#13
K Albrecht, A Richter, Y Meissner, D Huscher, L Baganz, K Thiele, M Schneider, A Strangfeld, A Zink
BACKGROUND: Unfavorable prognostic factors-high disease activity, early erosions, and autoantibodies-should be considered when making treatment decisions in rheumatoid arthritis (RA). There are little data on the frequency of individual poor prognostic factors among RA patients in daily care. METHODS: Disease activity (Disease Activity Score, DAS28), erosions, antibodies against citrullinated peptides or rheumatoid factor (ACPA/RF+), previous treatment failure, inflammation markers, and functional disability (FFbH < 70) were defined as prognostic factors...
April 20, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28416614/modeling-combined-immunosuppressive-and-anti-inflammatory-effects-of-dexamethasone-and-naproxen-in-rats-predicts-the-steroid-sparing-potential-of-naproxen
#14
Xiaonan Li, Debra C DuBois, Dawei Song, Richard R Almon, William J Jusko, Xijing Chen
Dexamethasone (DEX), a widely prescribed corticosteroid (CS), has long been the cornerstone for the treatment of inflammation and immunological dysfunctions in Rheumatoid Arthritis (RA). The CS are frequently used in combination with other anti-rheumatic agents such as nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying anti-rheumatic drugs (DMARDs) to mitigate disease symptoms and minimize unwanted effects. The steroid dose-sparing potential of the NSAID naproxen (NPX) was explored with in vitro and in vivo studies...
April 17, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28415924/an-assessment-of-the-current-treatment-landscape-for-rheumatology-patients-in-qatar-recognising-unmet-needs-and-moving-towards-solutions
#15
Samar Al Emadi, Mohammed Hammoudeh, Mohamed Mounir, Ruediger B Mueller, Alvin F Wells, Housam Aldeen Sarakbi
Objective This study assessed the mode of application (oral, intravenous or subcutaneous (SC)) currently employed in the treatment of rheumatoid arthritis (RA) in patients from Qatar in comparison with patients' individual preferences for the mode of application of their treatment. Methods This study included 294 RA patients visiting three clinics at the main referral hospital in Qatar who were interviewed using a standard questionnaire to determine their preference of mode of application for their disease-modifying antirheumatic drug (DMARD) treatment in relation to their currently employed mode of application...
April 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28412710/triple-oral-therapy-versus-antitumor-necrosis-factor-plus-methotrexate-mtx-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-mtx-a-systematic-literature-review
#16
Julia Mary, Michel De Bandt, Cédric Lukas, Jacques Morel, Bernard Combe
OBJECTIVE: For patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX), the relative effectiveness of the combination of conventional disease-modifying antirheumatic drugs (DMARD) compared with the combination of tumor necrosis factor (TNF) inhibitors and MTX, as second-line therapy, is uncertain. The aim of this study was to compare the efficacy and tolerance of triple oral DMARD therapy versus anti-TNF agents associated with MTX in patients with RA after MTX failure...
April 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28408801/effects-of-%C3%AE-d-mannuronic-acid-as-a-novel-non-steroidal-anti-inflammatory-medication-within-immunosuppressive-properties-on-il17-ror%C3%AE-t-il4-and-gata3-gene-expressions-in-rheumatoid-arthritis-patients
#17
Anis Barati, Ahmad Reza Jamshidi, Hossein Ahmadi, Zahra Aghazadeh, Abbas Mirshafiey
Rheumatoid arthritis (RA) is the most common form of chronic inflammatory arthritis characterized by pain, swelling and destruction of joints, with a resultant disability. Disease-modifying anti-rheumatic drugs (DMARDs) and biological drugs can interfere with the disease process. In this study, the effect of β-d-mannuronic acid (M2000) as a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive and anti-inflammatory effects together with antioxidant effects was evaluated on IL17, RORγt, IL4 and GATA3 gene expression in 12 RA patients...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28408798/an-open-randomized-active-controlled-clinical-trial-with-low-dose-ska-cytokines-versus-dmards-evaluating-low-disease-activity-maintenance-in-patients-with-rheumatoid-arthritis
#18
RANDOMIZED CONTROLLED TRIAL
L S Martin-Martin, F Giovannangeli, E Bizzi, U Massafra, E Ballanti, M Cassol, A Migliore
BACKGROUND: Biologic agents are currently the strongest immunosuppressive drugs able to induce remission in rheumatoid arthritis (RA). One of the objectives of the medical scientific community now is how to maintain remission or low disease activity (LDA). The aim of this trial is to evaluate the contribution of low-dose sequential kinetic activation (SKA) IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA in maintaining LDA or remission obtained after biological therapy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28405473/patient-reported-outcomes-from-a-phase-iii-study-of-baricitinib-in-patients-with-conventional-synthetic-dmard-refractory-rheumatoid-arthritis
#19
Paul Emery, Ricardo Blanco, Jose Maldonado Cocco, Ying-Chou Chen, Carol L Gaich, Amy M DeLozier, Stephanie de Bono, Jiajun Liu, Terence Rooney, Cecile Hsiao-Chun Chang, Maxime Dougados
OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily (QD, N=229) or baricitinib 4 mg QD (N=227). PROs included the Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, measures from patient electronic daily diaries (duration and severity of morning joint stiffness (MJS), Worst Tiredness, Worst Joint Pain), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), SF-36, EuroQol 5-D index scores and visual analogue scales (VAS) and the Work Productivity and Activity Impairment Questionnaire-RA...
2017: RMD Open
https://www.readbyqxmd.com/read/28403797/is-the-treatment-with-biological-or-non-biological-dmards-a-modifier-of-periodontal-condition-in-patients-with-rheumatoid-arthritis
#20
Consuelo Romero-Sanchez, Constanza Rodríguez, Pedro Santos, Ana María Mesa, Gloria Inés Lafaurie, Sebastian Giraldo, Juliette De Avila, Diana Marcela Castilla, Michelle Durán, Philippe Chalem, Juan Manuel Bello, Rafael Valle
BACKGROUND AND OBJECTIVE: Experimental models suggest the use of different therapy protocols in rheumatoid arthritis (RA) as modulators on periodontal condition. This study evaluated the effects of conventional drug treatment and anti-TNF therapy in patients with RA on microbiological and periodontal condition, establishing the association of markers of periodontal infection with indexes of rheumatic activity. MATERIALS AND METHODS: One hundred seventy nine individuals with RA were evaluated (62 with anti-TNF-α and 115 with only DMARDs)...
April 7, 2017: Current Rheumatology Reviews
keyword
keyword
2404
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"